Cross-Sector entity

TB-500

Company
5.7

Of the tracked stories, 3 of 3 also mention BPC-157, the most common co-covered peer. That works out to roughly 2.1 stories per week across a 10-day span. The busiest single day carried 2. regulation accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder.

3 verified stories tracked

Last mentioned: Aug 5, 2026

RSS updates
Share

Entity pulse

Recent coverage · TB-500

↑
3 stories
5.7 avg impact
67% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.

  • 67% positive
  • 33% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about TB-500

Of the tracked stories, 3 of 3 also mention BPC-157, the most common co-covered peer. That works out to roughly 2.1 stories per week across a 10-day span. The busiest single day carried 2. regulation accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The tracked stories average 2.3 original sources each. This profile follows 3 Cross-Sector stories mentioning TB-500 across the period from July 27, 2026 to August 5, 2026.

Stories tracked
3
Per week
2.1
Sources per story
2.3

Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering TB-500. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Advisory meeting concludes

    The committee is expected to wrap up its evaluation and make recommendations that will guide the FDA's future compounding policy for peptides.

Stories mentioning TB-500 3

Healthcare regulation Neutral 5

FDA Panel Reviews 7 Injectable Peptides Poised to Disrupt Telehealth and Longevity Care

The FDA’s advisory committee meeting on seven unapproved injectable peptides could reshape the rapidly growing telehealth and wellness industry. A decision to allow compounding would legitimize a key offering for direct-to-consumer platforms, while a restrictive stance may intensify safety risks from the gray market. Healthcare providers and digital health innovators are watching closely.

3 sources

Source: kpbs.org · wkyufm.org

Healthcare regulation Positive 6

FDA Panel's 8-6 Vote Opens Door for Peptide-Fueled Telehealth Boom

A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.

2 sources